Comparison between effect of glimepiride and pioglitazone on the C-reactive protein level of type 2 diabetic patient

Background: this study was carried out to see the effect of glimepiride and pioglitazone on the serum hs-crp level in type 2 diabetic patients. material and methods: a non-blind comparative study was conducted among 70 patients with type 2 diabetes (as per who criteria) divided into two groups (35 each) to see the effect of glimepiride and pioglitazone on their blood hs-crp level. results: 35 type-2 diabetic patients were given glimepiride. another 35 patients were given pioglitazone. fasting blood sugar,hba1 c%,hs-crp and lipid profile were estimated before and 12 weeks after intervention. the mean change of serum hs-crp was 1.13 mg/l to 0.76 mg/l in pioglitazone group. in glimepiride group the mean change of serum hs-crp was 0.96 mg/l to 0.94 mg/l after 12 weeks. the change was greater in pioglitazone group in comparison to glimepiride group. conclusion: reduction of hs-crp was significant in the study subjects revealing its future potential in reducing the vascular complications of type - 2 diabetes mellitus.